A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	Recruiting	Phase 1 / Phase 2	2026-05-05		NCT06214143

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Shanghai Pharmaceuticals Holding Co., Ltd	20

22 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Anyang Cancer Hospital	Anyang	China	4
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center	Shenzhen	China	6
Dongguan People's Hospital	Dongwan	China	1
Fujian Cancer Hospital	Fuzhou	China	37
Guangxi Medical University Affiliated Cancer Hospital	Nanning	China	2
Harbin Medical University Cancer Hospital	Ha’erbin	China	11
Henan Cancer Hospital	Zhengzhou	China	60
Hunan Cancer Hospital	Changsha	China	47
Jiangxi Cancer Hospital	Nanchang	China	18
Liaoning Cancer Hospital	Shenyang	China	14
Shandong Cancer Hospital	Jinan	China	19
Shanghai East Hospital	Shanghai	China	33
Shanghai ninth people's hospital	Shanghai	China	8
Shanxi Cancer Hospital	Taiyuan	China	17
Sichuan Cancer Hospital	Chengdu	China	21
Sun Yat-sen Memorial Hospital, Sun Yat-sen University	Guangzhou	China	24
The First Affiliated Hospital of Bengbu Medical University	Bengbu	China	14
The First Affiliated Hospital of Guangdong Pharmaceutical University	Guangzhou	China	1
The first affiliated hospital, Zhejiang university school of medicine	Hangzhou	China	27
The Second Affiliated Hospital of Zhejiang University School of Medicine	Hangzhou	China	17
Tianjin Cancer Hospital	Tianjin	China	10
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	37

Clinical trials